Cosmo Pharmaceuticals N.V. (SWX:COPN)

Market Cap	991.40M
Revenue (ttm)	170.24M
Net Income (ttm)	56.03M
Shares Out	15.94M
EPS (ttm)	3.43
PE Ratio	18.15
Forward PE	39.72
Dividend	1.91 (3.07%)
Ex-Dividend Date	Jun 4, 2025

Volume	46,605
Average Volume	25,275
Open	64.50
Previous Close	63.80
Day's Range	61.50 - 64.50
52-Week Range	41.60 - 70.90
Beta	1.28
RSI	36.42
Earnings Date	Mar 6, 2026

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1997
• Employees: 322
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: COPN

Financial Performance

Financial numbers in EUR